1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Gennex Laboratories Limited

Gennex Laboratories Limited

GENNEX.BO
Gennex Laboratories LimitedIN flagBombay Stock Exchange
10.03
INR
-0.21
- -
2.44BMarket Cap
Gennex Laboratories Limited
GENNEX.BO
(Bombay Stock Exchange)

Recent

price

10.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1.51
1.85
2.26
2.77
2.41
2.91
3.16
3.29
4.21
4.19
4.5
4.84
4.45
4.23
6.06
6.27
6.89
Revenue per Share
0.03
0.03
0.03
0.02
0.05
0.18
0.2
0.06
0.17
0.14
0.3
0.31
0.34
0.71
0.8
0.76
0.79
Basic EPS, GAAP
0.1
0.09
-0.18
-0.04
- -
0.16
-0.08
0.18
0.06
-0.15
-0.11
0.82
-1.1
-2.5
-0.87
-2.75
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.28
1.29
1.32
1.4
1.39
1.56
1.77
1.83
1.98
2.12
2.43
2.87
3.27
3.36
3.47
0.88
0.97
Book Value per Share
1.86
1.87
1.9
2.01
1.93
2.13
2.33
2.4
2.55
2.69
2.99
3.46
5.5
9.29
8.43
8.35
9.17
Tangible Book Value per Share
131
133
133
127
133
133
133
133
133
133
133
127
146
187
227
275
251
Basic Weighted Avg Shares
198
246
299
350
319
386
419
437
558
556
596
612
650
791
1,379
1,727
1,727
Sales/Revenue/Turnover
3.83
4.47
2.44
2.9
3.57
46.37
8.89
3.08
5.6
4.06
9.56
8.3
5.81
18.54
10.68
11.46
14.15
Operating Margin (%)
7
7
8
8
9
8
8
9
10
10
9
8
9
24
20
26
26
Depreciation Expense
4
4
4
2
7
23
27
8
22
19
40
39
49
132
181
210
197
Net Income, GAAP
15.48
42.82
16.36
70.46
22.79
22.96
12.79
42.49
26.64
27.16
20.23
22.98
22.79
20.11
15.2
9.48
9.6
Effective Tax Rate (%)
2.15
1.53
1.32
0.59
2.05
6.06
6.45
1.91
3.98
3.34
6.77
6.41
7.57
16.66
13.14
12.14
11.43
Profit Margin (%)
43
27
28
39
48
65
91
100
117
141
186
230
192
1,215
1,366
1,923
1,923
Working Capital
16
2
1
3
2
- -
1
3
- -
- -
- -
- -
163
132
169
434
434
LT Debt
244
248
252
254
255
282
309
318
338
357
397
438
865
1,765
1,946
2,328
2,328
Total Equity
2.47
2.4
2.28
1.08
3.05
45.59
9.78
2.22
6.17
3.99
9.91
7.45
3.57
7.61
5.81
6.51
8.03
Return on Invested Capital (%)
2.33
2.52
2.9
1.33
4.3
11.43
12.13
4.65
9.74
7.52
12.74
10.7
10.14
19.66
21
21.74
19.57
Return on Capital (%)
2.57
2.21
2.28
1.17
3.62
11.95
12.25
3.5
8.78
6.82
13.38
11.45
11.7
23.85
25.58
40.62
38.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
299
- -
360
LT Borrowings
586
- -
434
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
- -
243
Market Capitalization
2,551
3,375
1,787

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2,797
- -
2,647
Cash, Cash Equivalents & STI
480
- -
1,617
Accounts Receivable, Net
438
- -
436
Inventories
510
- -
539
Total Current Liabilities
762
- -
724
Payables & Accruals
- -
- -
- -
ST Debt
299
- -
360
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.72%
48.34%
19.66%
Free Cash Flow
-151.42%
-124.33%
282.86%
Net Income, GAAP
45.71%
48.73%
15.75%
Sales/Revenue/Turnover
17.77%
26.03%
25.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
165
176
191
259
791
2025
283
315
377
403
1,379
2026
342
372
404
610
1,727

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.16
0.16
- -
0.71
2025
0.21
0.21
0.22
0.14
0.8
2026
0.22
0.21
0.22
0.16
0.76

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
China BCT Pharmacy Group, Inc. (CNBI)
Stayble Therapeutics AB (publ) (STABL.ST)
Chong Kun Dang Pharmaceutical Corp. (185750.KS)
Santhera Pharmaceuticals Holding AG (SPHDF)
Entia Biosciences, Inc. (ERGO)
Nippon Shinyaku Co., Ltd. (NPPNY)
Business
Gennex Laboratories Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates and biotech products including Guaifenesin, an expectorant; Methocarbamol, a skeletal muscle relaxant; Fexofenadine HCl, an antihistamine; Phenazopyridine HCl, a urinary tract analgesic; Fluconazole, an antifungal; Melitracen HCl, a tricyclic antidepressant; Mephenesin and Chlorphenesin, muscle relaxants; Sertraline HCl, a selective serotonin reuptake inhibitor; and Allopurinol, a xanthine oxidase inhibitor. The company operates manufacturing facilities in IDA Bollaram and registered office in Hyderabad, Telangana, India, with exports to markets including Algeria, Bangladesh, Brazil, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand and Vietnam. Incorporated in 1985 as Pharmasia Drugs and Chemicals Private Limited and renamed from Prudential Pharmaceuticals Limited, Gennex Laboratories maintains ISO 9001:2008, ISO 14001 and OHSAS 18001 certifications. Its subsidiary Deccan Remedies Limited received approval from the Drugs Control Administration, Government of Andhra Pradesh, in 2025 for manufacturing additional products under Form 25, valid until May 2028 for domestic and export purposes; the company allotted over 155 lakh equity shares upon conversion of warrants to promoter group members on a preferential basis in June, July and November 2025; and appointed Sandeep Kumar Daga as additional non-executive non-independent director while noting resignations of directors including Dr. S Ch Dharma Rao and Mohammed Khaleequr Rahman in 2025.